Kevin Killeen | CSO

Kevin Killeen, CSO, Matrivax

Dr. Killeen joined Matrivax as Chief Scientific Officer in 2009. He has extensive training in the fields of vaccinology, molecular biology, microbiology, protein chemistry, and immunology. Dr Killeen’s experience includes identifying and leading the in-licensing effort of the  rotavirus vaccine candidate 89-12, now Rotarix®, a blockbuster vaccine commercialized by GSK. Prior to Matrivax, he led vaccine research and development programs at IDEXX Corp. and AVANT-Celldex. He directed 7 vaccine candidates into Phase 1 and 2 clinical trials, guided the R&D of CholeraGarde®, an oral, single-dose, cholera vaccine into a Phase 3 clinical trial, and commercialized two diagnostic tests. He has authored dozens of peer-reviewed articles, chapters, reviews, is the inventor on multiple patents, is a former editor of the journal Human Vaccines and Immunotherapies, and a member of the Dean’s Advisory Council at URI. Dr. Killeen was the principal investigator on vaccine related grants and contracts exceeding $11 million and coordinated greater than $13 million in funding from the Bill & Melinda Gates Foundation. Dr. Killeen holds a Ph.D. in microbiology from the University of Rhode Island. He completed a post-doctoral fellowship at Harvard Medical School in molecular genetics and protein toxin chemistry.


Day 1 - November 28 @ 16:20

Safety & immunogenicity of MVX01 Pneumococcal Vaccine

Day 1 - November 28 @ 16:50

Panel: Beyond PCV13: Exploring the Future of Pneumococcal Disease Vaccines

  • The current state of pneumococcal disease vaccine development and the limitations of PCV13.
  • New approaches to vaccine development, such as protein-based vaccines, conjugate vaccines, and combination vaccines
  • The potential impact of new vaccines on disease prevention and public health
  • Case for maternal immunization?
  • Challenges and opportunities for vaccine development in low- and middle-income countries
last published: 02/Jan/24 12:15 GMT

back to speakers